Skip to main content

Table 2 Anthropometric, vital, and laboratory data at baseline and 1-year follow-up

From: Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study

Parameter Baseline 1-year follow-up Change P-value 1)
  n mean ± SD n mean ± SD n mean ± SD  
Body weight, kg 491 62.2 ± 12.4 434 63.5 ± 11.8 434 1.3 ± 4.3 ***
BMI, kg/m2 490 23.9 ± 4.0 433 24.4 ± 3.7 433 0.5 ± 1.6 ***
HbA1c, % 506 10.3 ± 2.0 482 7.5 ± 1.3 478 −2.7 ± 2.2 ***
FPG, mg/dL 254 217.3 ± 80.8 137 139.0 ± 48.7 91 −79.0 ± 92.9 ***
PPG, mg/dL 329 296.1 ± 96.0 380 178.2 ± 68.6 256 −115.9 ± 111.1 ***
Total cholesterol, mg/dL 439 201.4 ± 43.6 309 187.7 ± 35.9 286 −12.6 ± 44.2 ***
LDL-cholesterol, mg/dL 294 122.0 ± 34.0 383 110.5 ± 28.3 239 −11.0 ± 32.0 ***
HDL-cholesterol, mg/dL        
Men 277 50.0 ± 13.7 268 53.2 ± 15.2 234 3.1 ± 11.3 ***
Women 163 56.8 ± 15.9 151 58.1 ± 15.7 135 2.3 ± 12.1 *
Triglycerides, mg/dL 465 159.7 ± 132.0 447 138.0 ± 85.3 410 −19.7 ± 128.3 **
Creatinine, mg/dL 404 0.76 ± 0.42 422 0.86 ± 0.58 334 0.11 ± 0.66 **
SBP, mmHg 474 132.1 ± 18.5 466 132.8 ± 17.7 435 1.0 ± 20.6 N.S.
DBP, mmHg 474 76.5 ± 11.7 466 74.5 ± 10.8 435 −1.9 ± 12.4 **
  1. Abbreviations: BMI body mass index, DBP diastolic blood pressure, FPG fasting plasma glucose, Hb hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, PPG postprandial plasma glucose, SBP systolic blood pressure.
  2. 1)Paired t-test.
  3. N.S. not statistically significant, *P < .05, **P < .01, ***P < .001.